Literature DB >> 21671018

Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses.

Voralak Vichapat1, Hans Garmo, Lars Holmberg, Ian S Fentiman, Andrew Tutt, Cheryl Gillett, Margreet Lüchtenborg.   

Abstract

Studies comparing the prognosis after contralateral breast cancer (CBC) with that after unilateral breast cancer (UBC) shows conflicting results. We assessed the risk of breast cancer-specific death for women with metachronous CBC compared to those with a UBC in 8,478 women with invasive primary breast cancer registered in the Guy's and St. Thomas' Breast Cancer Tissue and Data Bank. Risk factors associated with breast cancer-specific death for women with CBC were estimated using Cox proportional hazards modelling. Prognoses after UBC and CBC were compared, with survival time for women with CBC calculated: (i) from CBC, (ii) from the initial cancer with CBC as a time-dependent covariate. Women diagnosed with CBC within 5 years after the initial primary breast cancer had a worse prognosis than those with CBC after 5 years and those with UBC. Women with CBC who had positive lymph nodes at the initial breast cancer diagnosis were at an increased risk of dying from breast cancer compared to those without [HR 2.5 (95% CI 1.5-4.0)]. For all stages of the initial breast cancer, a worse prognosis was observed after CBC. CBC increased the hazard originating from the initial cancer at any follow-up time, but the highest hazards were associated with a short interval to CBC. Metachronous CBC adds to the risk of dying from breast cancer. The risk increases substantially when it occurs shortly after the initial cancer, indicating a CBC in some instances may be an indicator of active distant disease. The occurrence of CBC implies a new surveillance and therapeutic situation.

Entities:  

Mesh:

Year:  2011        PMID: 21671018     DOI: 10.1007/s10549-011-1618-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.

Authors:  Julia Prater; Fabio Valeri; Dimitri Korol; Sabine Rohrmann; Silvia Dehler
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-23       Impact factor: 4.553

2.  Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.

Authors:  Shuning Ding; Xi Sun; Shuangshuang Lu; Zheng Wang; Xiaosong Chen; Kunwei Shen
Journal:  Breast       Date:  2021-03-20       Impact factor: 4.380

3.  Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.

Authors:  Roberto Pacelli; Manuel Conson; Laura Cella; Raffaele Liuzzi; Giancarlo Troncone; Vincenzo Iorio; Raffaele Solla; Antonio Farella; Stefania Scala; Clorindo Pagliarulo; Marco Salvatore
Journal:  J Radiat Res       Date:  2012-09-26       Impact factor: 2.724

4.  Patterns of metastasis in women with metachronous contralateral breast cancer.

Authors:  V Vichapat; H Garmo; L Holmberg; I S Fentiman; A Tutt; C Gillett; M Lüchtenborg
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

5.  Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

Authors:  Annemieke Witteveen; Annemiek B G Kwast; Gabe S Sonke; Maarten J IJzerman; Sabine Siesling
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.

Authors:  Jennifer C Melvin; Arnie D Purushotham; Hans Garmo; Sarah E Pinder; Ian S Fentiman; Cheryl Gillett; Anca Mera; Margreet Lüchtenborg; Lars Holmberg; Mieke Van Hemelrijck
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

7.  Comparative Analysis of Outcomes and Clinicopathological Characteristics of Synchronous and Metachronous Contralateral Breast Cancer: A Study of the SEER Database.

Authors:  Ruiyue Qiu; Wen Zhao; Jiao Yang; Yanwei Shen; Biyuan Wang; Pan Li; Andi Zhao; Qi Tian; Mi Zhang; Min Yi; Jin Yang; Danfeng Dong
Journal:  J Breast Cancer       Date:  2019-04-03       Impact factor: 3.588

8.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

Authors:  Kerstin Rhiem; Christoph Engel; Monika Graeser; Silke Zachariae; Karin Kast; Marion Kiechle; Nina Ditsch; Wolfgang Janni; Christoph Mundhenke; Michael Golatta; Dominic Varga; Sabine Preisler-Adams; Tilman Heinrich; Ulrich Bick; Dorothea Gadzicki; Susanne Briest; Alfons Meindl; Rita K Schmutzler
Journal:  Breast Cancer Res       Date:  2012-12-07       Impact factor: 6.466

Review 9.  Contralateral prophylactic mastectomy: current perspectives.

Authors:  Katharine Yao; Mark Sisco; Isabelle Bedrosian
Journal:  Int J Womens Health       Date:  2016-06-22

10.  Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database.

Authors:  Kaiwen Shen; Longdi Yao; Jinli Wei; Zhou Luo; Wang Yu; Huamin Zhai; Jianwen Wang; Luhong Chen; Deyuan Fu
Journal:  Cancer Med       Date:  2019-10-30       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.